LATE BREAKING ABSTRACT: Entrectinib (RXDX-101), an oral pan-Trk, ROS1, and ALK inhibitor in patients with advanced solid tumors harboring gene rearr...

Date 27 September 2015
Event European Cancer Congress 2015
Session Early Drug Development II
Topics Drug Development
Presenter Siena, S.